A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma

Anti-Cancer Drugs

Volumn 23, Issue 5, 2012, Pages 561-566

  Xiang, Xiao Jun ^a   Liu, Ya Wen ^a   Zhang, Ling ^a   Qiu, Feng ^a   Yu, Feng ^a   Zhan, Zheng Yu ^a   Feng, Miao ^a   Yan, Jun ^b   Zhao, Jian Guo ^c   Xiong, Jian Ping ^a  

^a NANCHANG UNIVERSITY   (China)

^b GANNAN MEDICAL UNIVERSITY   (China)

^c SHAOXING PEOPLE S HOSPITAL   (China)

Author keywords

5 fluorouracil; advanced small bowel adenocarcinoma; chemotherapy; leucovorin; oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FUNCTIONAL DISEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SMALL INTESTINE CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DUODENAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84859651041     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328350dd0d     Document Type: Article

References (29)

1. Neugut AI, Marvin MR, Rella VA, Chabot JA. An overview of adenocarcinoma of the small intestine. Oncology 1997; 11:529-536. (Pubitemid 127637953)
2. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63-71.
3. Qubaiah O, Devesa SS, Platz CE, Huycke MM, Dores GM. Small intestinal cancer: a population-based study of incidence and survival patterns in the United States, 1992 to 2006. Cancer Epidemiol Biomarkers Prev 2010; 19:1908-1918.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
5. Howe JR, Karnell LH, Menck HR, Scott-Conner C. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86:2693-2706. (Pubitemid 30004674)
6. Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19:143-149. (Pubitemid 46187488)
7. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101:518-526. (Pubitemid 38970602)
8. Fishman PN, Pond GR, Moore MJ, Oza A, Burkes RL, Siu LL, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29:225-231. (Pubitemid 44270929)
9. Moon YW, Rha SY, Shin SJ, Chang H, Shim HS, Roh JK. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 2010; 136:387-394.
10. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010; 199:797-803.
11. Crawley C, Ross P, Norman A, Hill A, Cunningham D. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 1998; 78:508-510. (Pubitemid 28360640)
12. Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser T, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69:290-294. (Pubitemid 41752796)
13. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10:132-137. (Pubitemid 40261952)
14. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcome in metastatic small bowel adenocarcinoma. Cancer 2008; 113:2038-2045.
15. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010; 21:1786-1793.
16. Xiong JP, Zhang L, Zhong LX, Qiu F, Xu J, Tao QS, et al. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs 2007; 18:1103-1107. (Pubitemid 47294904)
17. Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F, et al. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs 2009; 20:281-286.
18. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10. (Pubitemid 19099520)
20. Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI Regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy. Cancer 2011; 117:1422-1428.
21. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27:2598-2603.
22. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, et al. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol 2009; 39:54-61.
23. Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer 2011; 11:205.
24. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808-815. (Pubitemid 27074252)
25. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004; 101:2170-2176. (Pubitemid 39458670)
26. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909. (Pubitemid 46630593)
27. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucoverin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947. (Pubitemid 30644117)
28. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006-2012.
29. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237. (Pubitemid 41095086)